Valneva accelerates Lyme disease vaccine R&D project with Pfizer
pharmaphorum
DECEMBER 4, 2020
This investigational multivalent protein subunit vaccine targets the outer surface protein A (OspA) of the bacterium Borrelia that causes the disease, an established mechanism of action for a Lyme disease vaccine.
Let's personalize your content